Heptares Therapeutics Ltd. - Product Pipeline Review - 2014

Published: Sep, 2014 | Pages: 41 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Heptares Therapeutics Ltd. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Heptares Therapeutics Ltd. - Product Pipeline Review - 2014', provides an overview of the Heptares Therapeutics Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Heptares Therapeutics Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Heptares Therapeutics Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Heptares Therapeutics Ltd.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Heptares Therapeutics Ltd.'s pipeline products

Reasons to buy

- Evaluate Heptares Therapeutics Ltd.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Heptares Therapeutics Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Heptares Therapeutics Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Heptares Therapeutics Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Heptares Therapeutics Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Heptares Therapeutics Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Heptares Therapeutics Ltd. Snapshot 5
Heptares Therapeutics Ltd. Overview 5
Key Information 5
Key Facts 5
Heptares Therapeutics Ltd. - Research and Development Overview 6
Key Therapeutic Areas 6
Heptares Therapeutics Ltd. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Pipeline Products - Out-Licensed Products 13
Out-Licensed Products/Combination Treatment Modalities 14
Heptares Therapeutics Ltd. - Pipeline Products Glance 15
Heptares Therapeutics Ltd. - Clinical Stage Pipeline Products 15
Phase I Products/Combination Treatment Modalities 15
Heptares Therapeutics Ltd. - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Discovery Products/Combination Treatment Modalities 17
Heptares Therapeutics Ltd. - Drug Profiles 18
HTL-9936 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Drug to Agonize Muscarinic M1/M4 Receptors for CNS Disorders 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Small Molecule to Agonize GLP-1 Receptor for Type 2 Diabetes 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Small Molecule to Agonize GPR-39 for Type 2 Diabetes 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Small molecule to Antagonize CGRP for Migraine 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Small Molecule to Antagonize mGluR5 for Autism, Depression and Dyskinesia 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Small Molecule to Antagonize Orexin 1 for Addiction and Compulsive Disorders 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Small Molecule to Target mGluR2 for Schizophrenia 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Monoclonal antibody to Target GPCR for Pain, Metabolic Disorders And Inflammation 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Small Molecule to Antagonize Orexin 1/2 for Insomnia 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Small Molecule to Target Chemokine (C-X-C Motif) Receptor 4 for Cancer and HIV 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecule to Target GPCR for CNS Disorders 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Small Molecules Targeting GPCR 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Small Molecules to Target GPCRs for Pain, Metabolic Disorders and Inflammation 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Heptares Therapeutics Ltd. - Pipeline Analysis 32
Heptares Therapeutics Ltd. - Pipeline Products by Target 32
Heptares Therapeutics Ltd. - Pipeline Products by Route of Administration 34
Heptares Therapeutics Ltd. - Pipeline Products by Molecule Type 35
Heptares Therapeutics Ltd. - Pipeline Products by Mechanism of Action 36
Heptares Therapeutics Ltd. - Recent Pipeline Updates 37
Heptares Therapeutics Ltd. - Locations And Subsidiaries 39
Head Office 39
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 41
Disclaimer 41

List of Tables
Heptares Therapeutics Ltd., Key Information 5
Heptares Therapeutics Ltd., Key Facts 5
Heptares Therapeutics Ltd. - Pipeline by Indication, 2014 8
Heptares Therapeutics Ltd. - Pipeline by Stage of Development, 2014 9
Heptares Therapeutics Ltd. - Monotherapy Products in Pipeline, 2014 10
Heptares Therapeutics Ltd. - Partnered Products in Pipeline, 2014 11
Heptares Therapeutics Ltd. - Partnered Products/ Combination Treatment Modalities, 2014 12
Heptares Therapeutics Ltd. - Out-Licensed Products in Pipeline, 2014 13
Heptares Therapeutics Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2014 14
Heptares Therapeutics Ltd. - Phase I, 2014 15
Heptares Therapeutics Ltd. - Preclinical, 2014 16
Heptares Therapeutics Ltd. - Discovery, 2014 17
Heptares Therapeutics Ltd. - Pipeline by Target, 2014 33
Heptares Therapeutics Ltd. - Pipeline by Route of Administration, 2014 34
Heptares Therapeutics Ltd. - Pipeline by Molecule Type, 2014 35
Heptares Therapeutics Ltd. - Pipeline Products by Mechanism of Action, 2014 36
Heptares Therapeutics Ltd. - Recent Pipeline Updates, 2014 37